Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Annexon Inc
ANNXCurrent price
5.75 USD
-0.1 USD (-1.71%)
Last closed
5.82 USD
Company
www.annexonbio.com
ISIN
US03589W1027
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
602 227 776 USD
Yield for 12 month
+142.62 %
1Y
3Y
5Y
10Y
15Y
ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Address: 1400 Sierra Point Parkway, Brisbane, CA, United States, 94005
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
16.4 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-3 267 000 USD
Last Year
-3 311 000 USD
Current Quarter
-856 000 USD
Last Quarter
-846 000 USD
Key Figures ANNX
1 year
3 years
5 years
10 years
EBITDA
-124 791 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-24.83 %
PEG Ratio
–
Return On Equity TTM
-42.2 %
Wall Street Target Price
16.4 USD
Revenue TTM
–
Book Value
3.42 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.21 USD
Diluted Eps TTM
-1.21 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ANNX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ANNX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ANNX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-2.4694
Price Book MRQ
1.6649
Financials ANNX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ANNX
For 52 weeks
1.57 USD
8.4 USD
50 Day MA
5.61 USD
Shares Short Prior Month
7 138 539
200 Day MA
4.94 USD
Short Ratio
5.74
Shares Short
7 274 207
Short Percent
8.24 %
BeatStart